ikarovec
Andrew Osborne is currently the Head of Biology at Ikarovec Limited. With previous experience as a Lead Investigator at Astellas Pharma and Principal Investigator at Quethera, Andrew has a strong background in research. Prior to their industry roles, Andrew also served as a Postdoctoral Research Fellow at the University of Cambridge. Andrew holds a PhD in Ocular Pharmaceutical Cell Biology from the University of East Anglia, where Andrew also completed their BSc in Biological Sciences.
This person is not in any teams
ikarovec
The company has an early stage pipeline of novel, multi-cistronic gene therapy products targeting diabetic macular edema (DME), age-related macular degeneration (AMD, both wet and dry forms) and ocular hypertension.